Macquarie buys Korean drug company Genuone Sciences in $550m deal

Macquarie Asset Management’s private equity fund is understood to have sealed the deal to acquire a 100% stake in Korean contract development and manufacturing organisation (CDMO) Genuone Sciences from local investor IMM Private Equity, according to sources familiar with the matter.